Back

Dose-response and efficacy ceiling of zilebesiran: a bayesian non-linear spline meta-analysis of phase 1 and KARDIA phase 2 trials

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic aspects for hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Krish Sumir Keswani

Vadodara (India)

6 More presentations in this session

Presentation thumbnail
Nationwide use of antihypertensive combination therapy in the Czech Republic
Professor J. Vaclavik (Ostrava, CZ)
Abstract Slides
Presentation thumbnail
Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry
Doctor C. Basile (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Autonomous closed-loop intravenous esmolol for systolic blood pressure regulation and beat-to-beat variability suppression with safety supervision: a large-animal validation study
Doctor J. Curneen (Galway, IE)
Abstract Slides
Presentation thumbnail
A multidimensional primary care intervention reduces sedentary behaviour and promotes behavioural readiness for physical activity in hypertension and diabetes patients
Doctor M. Marcolino (Belo Horizonte, BR)
Abstract Slides
Presentation thumbnail
The results of a standardized diagnostic care pathway in patients referred for difficult-to-treat hypertension: the IDENTIFY study
Miss K. Saville (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Therapeutic aspects for hypertension

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
19 February 2026
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT
1 September 2025
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019
thumbnail
Congress Presentation
Association between dose of medications and mortality in heart failure with reduced ejection fraction: a systematic review and dose-response meta-analysis
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources